Synedica Cagri Reta 40mg/4mg Dual Injection Pen Kit

The Synedica Cagri Reta 40mg/4mg Dual Injection Pen Kit is a dual-pen research product containing two investigational peptide compounds: retatrutide (40mg) and cagrilintide (4mg). According to available product listings, the kit contains two separately packaged pens, allowing each compound to be identified individually for research and product documentation purposes.

Retatrutide and cagrilintide are being investigated for their roles in metabolic signalling, appetite regulation, and energy balance. Although both compounds have attracted scientific interest, the safety and effectiveness of this specific combination have not been established for routine clinical use.

Product Specifications

• Product Name: Synedica Cagri Reta 40mg/4mg Dual Injection Pen Kit
• Retatrutide Content: 40mg
• Cagrilintide Content: 4mg
• Packaging Format: Dual injection pen kit
• Package Contents: Two pens, with needles and an instruction booklet where confirmed by the supplier
• Product Category: Investigational peptide research
• Intended Purpose: Research and development, subject to applicable regulations

Understanding the Two Compounds

Retatrutide 40mg

Retatrutide is an investigational peptide that acts on three receptor pathways: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. Clinical studies are investigating its effects on metabolic regulation and body weight. It is not an approved medicine for routine use.

Cagrilintide 4mg

Cagrilintide is a long-acting amylin analogue being studied for its role in appetite-related signalling and metabolic regulation. Research explores how amylin-related pathways influence satiety and energy balance.

Research into Complementary Metabolic Pathways

The two compounds act through different receptor systems, making their individual mechanisms relevant to metabolic research. However, findings about either compound alone should not be interpreted as proof that their combination is safe or effective.

Key Product Features

• Dual-pen packaging containing two separately identified compounds
• Clearly stated nominal ingredient strengths
• Research relevance to metabolic and peptide science
• Separate product identification for each pen
• Product documentation and batch verification should be checked before procurement

Package Contents

The product is listed as containing:

• 1 × Retatrutide 40mg pen
• 1 × Cagrilintide 4mg pen
• Additional accessories, such as disposable needles and an instruction booklet, subject to confirmation against the actual package

Storage and Product Verification

Follow the storage conditions stated on the manufacturer’s current product label. Request batch-specific documentation, including a Certificate of Analysis (CoA), and check the batch number, identity testing, reported purity, and expiry information where applicable.

Do not assume that a product is sterile, authentic, or suitable for injection merely because it is supplied in a prefilled pen or carries a research-use label.

Important Research Disclaimer

The Synedica Cagri Reta 40mg/4mg Dual Injection Pen Kit should not be presented as an approved weight-management medicine. Retatrutide remains investigational, and the clinical safety and efficacy of this particular combination have not been established for routine human use.

This product description is for research and informational purposes only. It does not provide dosing instructions or recommend self-administration. Products intended for research must be handled in accordance with applicable laws and appropriate laboratory procedures.